Zepbound added $4.9 billion in US sales and oral Foundayo made $98 million in its first quarter. Both companies report Q3 results on Oct. 29.
Recap by typeshit. Full story at The Motley Fool.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
A 2025 Kinsey Institute survey found more than half of users saw sex life changes, split both ways. Doctors quoted say solid causal evidence is still missing.
Healio
Three months after the ADJUST-T1D trial ended, people who had been on semaglutide saw time in range drop 3.6 points, while those on placebo gained 1.5 points.
Loading…